RIPK1 and hepatocellular carcinoma: In TNF-related apoptosis-inducing ligand (TRAIL)-resistant HCC cells, CASC2 targeted miR-18a/receptor-interacting serine/threonine-protein kinase 1 (RIPK1) axis and the NF-kappa B pathway, whereas in TRAIL-sensitive cells, CASC2 affected miR-221/caspase-3 and miR-24/caspase-8 (115).